Data Insights

Nisevokitug by Novartis for Metastatic Colorectal Cancer: Likelihood of Approval

Nisevokitug is under clinical development by Novartis and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Metastatic Colorectal Cancer

Data Insights

Trametinib dimethyl sulfoxide by Novartis for High-Grade Glioma: Likelihood of Approval

Trametinib dimethyl sulfoxide is under clinical development by Novartis and currently in Phase II for High-Grade Glioma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in High-Grade Glioma

Data Insights

Nisevokitug by Novartis for Solid Tumor: Likelihood of Approval

Nisevokitug is under clinical development by Novartis and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Solid Tumor

Data Insights

Ribociclib succinate by Novartis for High-Grade Glioma: Likelihood of Approval

Ribociclib succinate is under clinical development by Novartis and currently in Phase II for High-Grade Glioma. According to GlobalData, Phase...

Data Insights

Siremadlin succinate by Novartis for Metastatic Colorectal Cancer: Likelihood of Approval

Siremadlin succinate is under clinical development by Novartis and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Data Insights

Nisevokitug by Novartis for Myelofibrosis: Likelihood of Approval

Nisevokitug is under clinical development by Novartis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Myelofibrosis

Data Insights

Nisevokitug by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Nisevokitug is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Nisevokitug by Novartis for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Nisevokitug is under clinical development by Novartis and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Data Insights

Trametinib dimethyl sulfoxide by Novartis for Relapsed Multiple Myeloma: Likelihood of Approval

Trametinib dimethyl sulfoxide is under clinical development by Novartis and currently in Phase II for Relapsed Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in Relapsed Multiple Myeloma

Data Insights

Tesidolumab by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval

Tesidolumab is under clinical development by Novartis and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase...

Data Insights

Crizanlizumab by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Crizanlizumab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

LKA-651 by Novartis for Diabetic Macular Edema: Likelihood of Approval

LKA-651 is under clinical development by Novartis and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase...

Data Insights

Spartalizumab by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Spartalizumab is under clinical development by Novartis and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....

Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Crizanlizumab by Novartis for Myelofibrosis: Likelihood of Approval

Crizanlizumab is under clinical development by Novartis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Myelofibrosis

Data Insights

Gene Therapy 1 to Target CD22 for B-Cell Acute Lymphoblastic Leukemia by Novartis for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Gene Therapy 1 to Target CD22 for B-Cell Acute Lymphoblastic Leukemia is under clinical development by Novartis and currently in...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy 1 To Target CD22 For B-Cell Acute Lymphoblastic Leukemia in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Sabatolimab by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Sabatolimab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Risk adjusted net present value: What is the current valuation of Novartis's LNA-043?

LNA-043 is a biologic commercialized by Novartis, with a leading Phase II program in Osteoarthritis. According to Globaldata, it is...

Net Present Value Model: Novartis AG's LNA-043

Data Insights

Risk adjusted net present value: What is the current valuation of Novartis's Pelacarsen Sodium?

Pelacarsen Sodium is an antisense oligonucleotide commercialized by Novartis, with a leading Phase III program in Cardiovascular Disease. According to...

Net Present Value Model: Novartis AG's Pelacarsen Sodium

Data Insights

Risk adjusted net present value: What is the current valuation of Novartis's Peptide to Antagonize GRPR for Oncology?

Peptide to Antagonize GRPR for Oncology is a peptide commercialized by Novartis, with a leading Phase II program in Metastatic...

Net Present Value Model: Novartis AG's Peptide to Antagonize GRPR for Oncology

Data Insights

Risk adjusted net present value: What is the current valuation of Novartis's Iscalimab?

Iscalimab is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Lupus Nephritis. According to Globaldata,...

Net Present Value Model: Novartis AG's Iscalimab